88016-17-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyrrolidinone,4-amino-(9CI) is used as a precursor in the synthesis of pharmaceuticals for its ability to contribute to the development of various medicinal compounds. Its reactivity allows it to be a key component in creating new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Pyrrolidinone,4-amino-(9CI) serves as a precursor in the synthesis of agrochemicals, playing a crucial role in the development of products designed to enhance crop protection and improve agricultural yields.
Used in Organic Synthesis:
2-Pyrrolidinone,4-amino-(9CI) is utilized as a versatile building block in organic synthesis, enabling the creation of a wide range of organic compounds for various applications across different industries. Its capacity to form diverse chemical products underscores its importance in advancing chemical manufacturing processes.

Upstream product

• 899806-32-7 (S)-4-azidopyrrolidin-2-one 
• 1346773-63-4 [(3R)-5-oxopyrrolidin-3-yl]carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

PYRROLIDINE DERIVATIVES WITH ANTIBACTERIAL PROPERTIES

Provided is a compound of Formula (I) or a salt thereof: Formula (I) wherein R, m, n, R1, R2, Aa-Ac are defined as in the claims and ArI represents a bicyclic heterocyclic group of the following formula: Formula (2) Ar 2 represents a bicyclic heterocyclic group of the formula: [Formula 3] having antibacterial activity.

HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structure: (I) wherein R1 , R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

Synthesis of (R)-3,4-diaminobutanoic acid by desymmetrization of dimethyl 3-(benzylamino)glutarate through enzymatic ammonolysis

Lipase B from Candida antarctica is shown to be a highly efficient catalyst for the desymmetrization of dimethyl 3-(benzylamino)glutarate (1) through aminolysis and ammonolysis reactions. Using this procedure, enantiopure monoamides are obtained in high yield. The synthetic value of these compounds is demonstrated by the preparation of an enantiopure nonnatural amino acid, i.e. (R)-3,4-diaminobutanoic acid [(+)-12].